ALG-000184, Publications ALG-000184 (300 mg) ± Entecavir Results in Substantial HBV Antigen Declines in Untreated HBeAg-Positive Subjects with CHB
ALG-055009, Publications Pharmacodynamics of Multiple Ascending Oral Doses of ALG-055009, a THR β Agonist, in Hyperlipidemic Subjects
Publication, Publications Synthesis and evaluation of highly potent HBV capsid assembly modulators (CAMs)
ALG-000184, Publications Long-term Dosing with ALG-000184 in HBeAg Positive Subjects Results in Unprecedented Multi-log Reductions in HBV Markers Including HBsAg
Preclinical, Publications Class-A Cams Induce Cell Death Through HBV Core Protein Aggregation And Potentially Activate The Innate Immune Response
Preclinical, Publications Discovery of a Liver Targeted Oral PD-L1 Small Molecule Inhibitor for the Treatment of Chronic Hepatitis B and Liver Cancer
ALG-055009, Publications Nonclinical Efficacy, Pharmacokinetic/Pharmacodynamic (PK/PD), and Toxicology Profile of ALG-055009, a Novel and Potent Thyroid Hormone Receptor β Agonist, for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)
ALG-000184, Publications Preclinical Resistance Profile and Antiviral Activity of the Best-in-Class CAM-E ALG-001075, the Parent Compound of ALG-000184
ALG-055009, Publications Safety, Pharmacokinetics, And Pharmacodynamics Of Multiple Ascending Oral Doses Of ALG-055009, A Thyroid Hormone Receptor Beta Agonist, In Hyperlipidaemic Subjects And Relative Bioavailability/food Effect Of A Solid Formulation In Healthy Volunteers
ALG-000184, Publications Prolonged (>24 Week) Dosing with the Oral CAM-E Compound ALG-000184 Results In Multi-log Reductions In Hepatitis B Surface Antigen, HBV DNA, And HBV RNA Levels In Untreated E Antigen Postive Subjects With Chronic Hepatitis B